Managers / Q1 2019 · view latest →
Mohican Financial Management, LLC
CIK 0001367663 · 21 RIVER RD, SUITE 2100, WILTON, CT, 06897 · 203-423-8029
Summary
Mohican Financial Management, LLC reported $31M in U.S.-listed holdings across 31 positions for Q1 2019.
Its largest position, Carbonite, represents 7.6% of the portfolio.
Compared with Q4 2018, the fund opened 4 new positions and exited 3.
Portfolio Metrics
Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.
Reported Value by Quarter
Portfolio Composition
- US DOMESTIC · 100.0% · $31M
Quarter-over-Quarter Changes full breakdown →
vs Q4 2018 (amended baseline)
| Issuer | Move | Share Δ | Shares now | Value Δ | Value now |
|---|---|---|---|---|---|
| Q2 HLDGS INC | NEW | +1.50M | 1.50M | +$2M | $2M |
| EZCORP INC | NEW | +1.00M | 1.00M | +$1M | $1M |
| VERINT SYS INC | NEW | +1.00M | 1.00M | +$1M | $1M |
| TWITTER INC | NEW | +651.0K | 651.0K | +$612,000 | $612,000 |
| INSMED INC | ADDED | +1.00M | 1.50M | +$1M | $2M |
| SERVICENOW INC | SOLD OUT | −1.00M | 0 | −$1M | $0 |
| ACETO CORP | SOLD OUT | −500.0K | 0 | −$355,000 | $0 |
| FLUIDIGM CORP DEL | SOLD OUT | −305.0K | 0 | −$347,000 | $0 |
Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.
Holdings — Q1 2019
| # | Issuer | Class | % Portfolio | Value ↓ | Shares |
|---|---|---|---|---|---|
| 1 | CARBONITE INC | NOTE 2.500% 4/0 | 7.60% | $2M | 2.00M |
| 2 | HELIX ENERGY SOLUTIONS GRP I | NOTE 4.125% 9/1 | 7.47% | $2M | 2.00M |
| 3 | Q2 HLDGS INC | NOTE 0.750% 2/1 | 6.44% | $2M | 1.50M |
| 4 | SILICON LABORATORIES INC | NOTE 1.375% 3/0 | 5.37% | $2M | 1.50M |
| 5 | KAMAN CORP | NOTE 3.250% 5/0 | 5.13% | $2M | 1.42M |
| 6 | INSMED INC | NOTE 1.750% 1/1 | 4.92% | $2M | 1.50M |
| 7 | RETROPHIN INC | NOTE 2.500% 9/1 | 4.86% | $1M | 1.60M |
| 8 | PACIRA PHARMACEUTICALS INC | NOTE 2.375% 4/0 | 4.78% | $1M | 1.50M |
| 9 | HARMONIC INC | NOTE 4.000%12/0 | 4.73% | $1M | 1.25M |
| 10 | EXACT SCIENCES CORP | NOTE 1.000% 1/1 | 4.58% | $1M | 1.00M |
| 11 | INFINERA CORPORATION | NOTE 2.125% 9/0 | 3.92% | $1M | 1.50M |
| 12 | ALDER BIOPHARMACEUTICALS INC | NOTE 2.500% 2/0 | 3.90% | $1M | 1.25M |
| 13 | EZCORP INC | NOTE 2.875% 7/0 | 3.68% | $1M | 1.00M |
| 14 | VERINT SYS INC | NOTE 1.500% 6/0 | 3.61% | $1M | 1.00M |
| 15 | II VI INC | NOTE 0.250% 9/0 | 3.49% | $1M | 1.00M |
| 16 | TEAM INC | NOTE 5.000% 8/0 | 3.44% | $1M | 967.0K |
| 17 | DEXCOM INC | NOTE 0.750% 5/1 | 2.25% | $690,000 | 525.0K |
| 18 | TWITTER INC | NOTE 1.000% 9/1 | 2.00% | $612,000 | 651.0K |
| 19 | SILVER STD RES INC | NOTE 2.875% 2/0 | 1.99% | $609,000 | 610.0K |
| 20 | FLEXION THERAPEUTICS INC | NOTE 3.375% 5/0 | 1.77% | $543,000 | 625.0K |
| 21 | VEECO INSTRS INC DEL | NOTE 2.700% 1/1 | 1.66% | $509,000 | 595.0K |
| 22 | NEW MTN FIN CORP | NOTE 5.750% 8/1 | 1.63% | $499,000 | 500.0K |
| 23 | THERAVANCE BIOPHARMA INC | NOTE 3.250%11/0 | 1.61% | $494,000 | 500.0K |
| 24 | AVID TECHNOLOGY INC | NOTE 2.000% 6/1 | 1.54% | $472,000 | 500.0K |
| 25 | FIREEYE INC | NOTE 1.625% 6/0 | 1.52% | $466,000 | 500.0K |
| 26 | ENCORE CAP EUROPE FIN LTD | NOTE 4.500% 9/0 | 1.48% | $453,000 | 500.0K |
| 27 | TIMKENSTEEL CORP | NOTE 6.000% 6/0 | 1.42% | $436,000 | 365.0K |
| 28 | ENCORE CAP GROUP INC | NOTE 2.875% 3/1 · NOTE 3.000% 7/0 | 1.40% | $429,000 | 461.0K |
| 29 | GLOBAL EAGLE ENTMT INC | NOTE 2.750% 2/1 | 0.95% | $290,000 | 500.0K |
| 30 | NOVAVAX INC | NOTE 3.750% 2/0 | 0.88% | $271,000 | 750.0K |
Filing History
| Quarter | Reported Value | Positions | Filed | Type | Links |
|---|---|---|---|---|---|
| Q2 2021 | $256M | 70 | Jul 28, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q1 2021 | $154M | 51 | Apr 29, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q4 2020 | $98M | 46 | Jan 14, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q3 2020 | $80M | 47 | Oct 20, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q2 2020 | $55M | 40 | Jul 20, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q1 2020 | $70M | 47 | Apr 29, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q4 2019 | $64M | 40 | Jan 28, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q3 2019 | $65M | 46 | Oct 25, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q2 2019 | $68M | 49 | Jul 11, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q1 2019 | $31M | 31 | Apr 23, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q4 2018 | $24M | 30 | Jan 29, 2019 | 13F-HR | changes · EDGAR ↗ |
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.